Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer - Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00031837

Locations


United States, Alabama
	MBCCOP - Gulf Coast
	Mobile, Alabama, United States, 36607

United States, Colorado
	CCOP - Colorado Cancer Research Program, Incorporated
	Denver, Colorado, United States, 80224

United States, Illinois
	CCOP - Central Illinois
	Decatur, Illinois, United States, 62526
	MBCCOP - University of Illinois at Chicago
	Chicago, Illinois, United States, 60612-7323

United States, Michigan
	CCOP - Kalamazoo
	Kalamazoo, Michigan, United States, 49007-3731

United States, Missouri
	CCOP - Kansas City
	Kansas City, Missouri, United States, 64131

United States, New York
	CCOP - Hematology-Oncology Associates of Central New York
	East Syracuse, New York, United States, 13057
	University of Rochester Cancer Center CCOP Research Base
	Rochester, New York, United States, 14642

United States, North Carolina
	CCOP - Southeast Cancer Control Consortium
	Goldsboro, North Carolina, United States, 27534-9479

United States, Ohio
	CCOP - Columbus
	Columbus, Ohio, United States, 43215
	CCOP - Dayton
	Dayton, Ohio, United States, 45429

United States, South Carolina
	CCOP - Greenville
	Greenville, South Carolina, United States, 29615

United States, Washington
	CCOP - Northwest
	Tacoma, Washington, United States, 98405-0986

Sponsors and Collaborators

University of Rochester

National Cancer Institute (NCI)

Investigators


Study Chair:	Kishan J. Pandya, MD	University of Rochester